| 000 | 03471naa a22005537i 4500 | ||
|---|---|---|---|
| 001 | UMUN-OA-20261005-MLS-056 | ||
| 003 | local | ||
| 005 | 20261005174905.0 | ||
| 006 | m o d | ||
| 007 | cr|||||||||||| | ||
| 008 | 261005s2022 xx o u000 0 eng d | ||
| 024 | 7 |
_a10.3389/fimmu.2022.927153 _2doi |
|
| 035 | _a(local)EuropePMC:PMC9226391 | ||
| 040 |
_alocal _beng _clocal |
||
| 041 | 0 | _aeng | |
| 100 | 0 |
_aXiaomin Zhang _eauthor. |
|
| 245 | 1 | 0 |
_aCAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. / _cXiaomin Zhang; Lingling Zhu; Hui Zhang [and others]. |
| 264 | 1 |
_a[Place of publication not identified] : _bFrontiers Media SA, _c2022. |
|
| 300 | _a1 online resource (1 article). | ||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 500 | _aPublication type: Review article. | ||
| 500 | _aLinked open-access copy: published version. | ||
| 506 | 0 |
_aOpen access; no subscription required for the linked open-access version. _fUnrestricted online access _2star |
|
| 520 | 3 | _aChimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer treatment, and it has achieved unprecedented success in hematological malignancies, especially in relapsed/refractory (R/R) B cell malignancies. At present, CD19 and BCMA are the most common targets in CAR-T cell therapy, and numerous novel therapeutic targets are being explored. However, the adverse events related to CAR-T cell therapy might be serious or even life-threatening, such as cytokine release syndrome (CRS), CAR-T-cell-related encephalopathy syndrome (CRES), infections, cytopenia, and CRS-related coagulopathy. In addition, due to antigen escape, the limited CAR-T cell persistence, and immunosuppressive tumor microenvironment, a considerable proportion of patients relapse after CAR-T cell therapy. Thus, in this review, we focus on the progress and challenges of CAR-T cell therapy in hematological malignancies, such as attractive therapeutic targets, CAR-T related toxicities, and resistance to CAR-T cell therapy, and provide some practical recommendations. | |
| 540 |
_aCreative Commons Attribution (licence family recorded by the source; version not supplied in metadata). _uhttps://europepmc.org/articles/PMC9226391 |
||
| 546 | _aIn English. | ||
| 588 | 0 | _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source. | |
| 590 | _aCourse allocation: B. Sc. Medical Laboratory Science. | ||
| 650 | 4 | _aHematological malignancies | |
| 650 | 4 | _aCombinatorial Therapy | |
| 650 | 4 | _aAntigen Escape | |
| 650 | 4 | _aImmunosuppressive Tumor Microenvironment | |
| 650 | 4 | _aCar-t Cell | |
| 650 | 4 | _aCar-t Related Toxicities | |
| 653 | _aB. Sc. Medical Laboratory Science | ||
| 653 | _aUMUN open access collection | ||
| 653 | _ahematology | ||
| 655 | 4 | _aReview articles. | |
| 700 | 0 |
_aLingling Zhu _eauthor. |
|
| 700 | 0 |
_aHui Zhang _eauthor. |
|
| 700 | 0 |
_aShanshan Chen _eauthor. |
|
| 700 | 0 |
_aYang Xiao _eauthor. |
|
| 773 | 0 |
_tFrontiers in immunology _gVol. 13, (2022), pages/article 927153 _x1664-3224 |
|
| 856 | 4 | 0 |
_uhttps://europepmc.org/articles/PMC9226391 _yRead open-access publication _zOpen access. _70 |
| 884 |
_aCourse selection and automated MARC21 enrichment from Europe PMC metadata. _g20261005 _khttps://europepmc.org/articles/PMC9226391 _qlocal |
||
| 942 | _n0 | ||
| 999 |
_c1198 _d1198 |
||